Capsida Biotherapeutics temporarily halted its Phase 1/2 clinical trial for a gene therapy targeting a rare neurodevelopmental disorder after the death of its first treated patient. The biotech is investigating the cause of the fatality. This event underscores the challenges and risks inherent to pioneering gene therapy for complex brain disorders, highlighting the need for cautious development and vigilant safety oversight in early-stage clinical testing of such advanced therapeutics.